Last updated on May 2019

Survey Study for Velaglucerase Alfa (VPRIV) in Japan


Brief description of study

The objective of this post-marketing survey study is to collect data to determine the safety and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new to therapy or have been switched from another therapeutic agent for Gaucher disease.

Clinical Study Identifier: NCT03625882

Find a site near you

Start Over

Konan

Konan, Japan
  Connect »

Nagoya

Nagoya, Japan
  Connect »

Kitakyushu

Kitakyushu, Japan
  Connect »

Kurume

Kurume, Japan
  Connect »

Fukuyama

Fukuyama, Japan
  Connect »

Higashihiroshima

Higashihiroshima, Japan
  Connect »

Obihiro

Obihiro, Japan
  Connect »

Sagamihara

Sagamihara, Japan
  Connect »

Sendai

Sendai, Japan
  Connect »

Suita

Suita, Japan
  Connect »

Tondabayashi

Tondabayashi, Japan
  Connect »

Kawagoe

Kawagoe, Japan
  Connect »

Tokorozawa

Tokorozawa, Japan
  Connect »

Moriyama

Moriyama, Japan
  Connect »

Otsu

Otsu, Japan
  Connect »

Matsue

Matsue, Japan
  Connect »

Hamamatsu

Hamamatsu, Japan
  Connect »

Iwata

Iwata, Japan
  Connect »

Minato

Minato, Japan
  Connect »

Sumida-ku

Sumida-ku, Japan
  Connect »

Yonago

Yonago, Japan
  Connect »

Chiba

Chiba, Japan
  Connect »

Gifu

Gifu, Japan
  Connect »

Hiroshima

Hiroshima, Japan
  Connect »

Kagoshima

Kagoshima, Japan
  Connect »

Kumamoto

Kumamoto, Japan
  Connect »

Kyoto

Kyoto, Japan
  Connect »

Okayama

Okayama, Japan
  Connect »

Osaka

Osaka, Japan
  Connect »

Saitama

Saitama, Japan
  Connect »

Shizuoka

Shizuoka, Japan
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.